Madison Clarke
Respiratory Syncytial Virus, or RSV, is a highly contagious virus that causes infections of the lungs and breathing passages. RSV usually causes mild, cold-like symptoms, but it can be severe in infants and older adults, leading to hospitalization and even death. The RSV vaccine helps protect older adults at risk of severe illness from RSV. The CDC recommends that all adults aged 75 and older receive the RSV vaccine, and adults aged 50-74 with certain risk factors for severe RSV disease should also get vaccinated.
| Characteristics | Values |
|---|---|
| Age recommendation | 75 or older |
| Age recommendation with conditions | 50-74 with certain chronic health conditions or living in a nursing home |
| Risk factors | Chronic heart or lung disease, a weakened immune system, other medical conditions such as diabetes |
| Number of vaccines | 3 |
| Companies | Pfizer, GSK, Moderna |
| Type of vaccine | Single dose |
| Time to get vaccinated | Late summer and early fall |
| Side effects | Pain, redness, swelling where the shot is given, fatigue, fever, headache, nausea, diarrhea, muscle or joint pain |
| Allergic reaction | Do not get the RSV shot if you are allergic to any of its ingredients |
| Sickness | Get the shot when you are feeling better |
Explore related products
What You'll Learn
RSV vaccine recommendations for people over 50
Respiratory syncytial virus (RSV) usually causes mild, cold-like symptoms, but it can be dangerous for infants, older adults, and those with certain health conditions. The CDC recommends that all adults over the age of 75 receive the RSV vaccine. This is because older adults are at a higher risk of developing severe RSV disease, which can lead to hospitalization and even death.
For adults between the ages of 50 and 74, the CDC recommends the RSV vaccine for those who are at an increased risk of severe RSV disease. This includes individuals with certain chronic medical conditions, such as lung or heart disease, or those living in nursing homes. The RSV vaccine can help protect these high-risk individuals from severe illness, hospitalization, and potential complications from RSV.
There are currently three RSV vaccines licensed by the U.S. Food and Drug Administration (FDA) for use in adults: GSK's Arexvy, Moderna's mResvia, and Pfizer's Abrysvo. These vaccines are given as a single dose and can be administered at any time, although late summer and early fall are recommended as this is before RSV usually starts to spread in communities. It is important to note that the RSV vaccine is not currently an annual vaccine, and individuals who have already received one dose do not need another at this time.
While the RSV vaccine is generally safe, some side effects may occur, such as pain, redness, and swelling at the injection site, as well as fatigue, fever, headache, nausea, diarrhea, and muscle or joint pain. These side effects are typically mild and comparable to those experienced with other vaccines. However, in rare cases, the GSK and Pfizer vaccines have been associated with an increased risk of Guillain-Barré syndrome (GBS), a rare neurological condition.
The CDC and FDA continue to monitor the safety and effectiveness of the RSV vaccine and will provide updates to their recommendations as new data becomes available.
Tdap Vaccine Ingredients: What's Inside?
You may want to see also
Explore related products
$25.99 $49.99
RSV vaccine side effects
Respiratory Syncytial Virus (RSV) vaccines are available for adults aged 50 and older, and for pregnant women. The vaccines are designed to prevent lower respiratory tract disease (LRTD) caused by RSV. While the vaccines are generally safe, they may cause certain side effects, which are typically mild and should get better within a few days.
Some common side effects include fatigue, fever, headache, nausea, and diarrhea. Injection site reactions, such as redness, pain, and swelling, are also common. Muscle and joint pain may occur, with muscle pain being reported more frequently. These side effects can be managed at home and should resolve within a few days. For example, applying ice to sore muscles may provide relief.
In rare cases, more serious side effects have been reported. A small number of participants in clinical trials developed Guillain-Barré syndrome (GBS), a rare neurological disorder where the immune system attacks the nerves, resulting in weakness or paralysis. There have also been reports of abnormal heart rhythms and facial paralysis. Severe allergic reactions, including anaphylaxis, are also possible, requiring immediate medical attention.
If you experience any side effects from an RSV vaccine, it is important to report them to the Vaccine Adverse Event Reporting System (VAERS). You can do this through your healthcare provider, the VAERS website, or by calling their hotline. It is always recommended to consult with your healthcare provider if you have any concerns or questions about side effects.
Immunological Memory: What's the Truth?
You may want to see also
Explore related products
RSV vaccine coadministration with other vaccines
Respiratory syncytial virus (RSV) is a highly contagious virus that causes infections of the lungs and breathing passages. It is especially dangerous for older adults, as it can cause life-threatening pneumonia. The RSV vaccine is recommended for all adults aged 75 and older and for adults aged 60-74 who are at an increased risk of severe RSV.
The RSV vaccine can be coadministered with other adult vaccines during the same visit. However, data on the immunogenicity of RSV vaccines when co-administered with other vaccines are currently limited. The available data suggest that co-administration may result in lower antibody titers, but the clinical significance of this is unknown. Co-administration may also increase common side effects such as pain at the injection site, fever, headache, and myalgia.
GSK's Arexvy, Moderna's mResvia, and Pfizer's Abrysvo are the three RSV vaccines licensed for use in adults aged 60 and older. Arexvy and Abrysvo are supplied in two vials that must be reconstituted prior to administration, while mResvia is supplied as a pre-filled syringe containing a frozen suspension that must be thawed prior to administration.
When deciding whether to co-administer the RSV vaccine with other vaccines, healthcare providers should consider the patient's risk factors for severe disease, the feasibility of the patient returning for additional doses, the risk of acquiring vaccine-preventable diseases, and the patient's preferences. It is important to note that GSK's Arexvy, Moderna's mResvia, and Pfizer's Abrysvo should not be administered to individuals with a history of severe allergic reactions to any component of the vaccine.
The CDC will continue to monitor the real-world effectiveness of the RSV vaccine and will provide updated guidance on vaccine co-administration as more data becomes available.
Antibodies: What They Don't Do and Why
You may want to see also
Explore related products
RSV vaccine for infants and toddlers
Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the U.S. and usually causes mild, cold-like symptoms. The CDC recommends two ways to protect babies from severe RSV: a maternal RSV vaccine or an RSV antibody for the baby.
The maternal RSV vaccine, Pfizer's Abrysvo, is given during weeks 32 to 36 of pregnancy and protects the baby for approximately six months after birth. The mother's immune system produces antibodies against RSV, which are transferred through the placenta to the baby. These antibodies help protect the infant from birth up to six months, while they are at the highest risk of severe RSV.
The RSV antibody, nirsevimab, can be given to babies and young children. It provides immediate protection against RSV and lasts at least five months. It is recommended for babies younger than eight months born to mothers who did not receive the maternal RSV vaccine. It is also recommended for young children aged eight to 19 months who are at increased risk of severe RSV. Nirsevimab is highly effective in preventing RSV-associated hospitalization, and side effects are usually mild.
Healthcare providers should discuss both options with parents and consider patient preferences when deciding which product is best for their family. The maternal RSV vaccine is free under the National Immunisation Program (NIP) in Australia, and nirsevimab is provided for free to eligible infants and children in some states and territories.
RSV vaccines and monoclonal antibodies are available in Australia but may require a prescription, and they do not offer protection against other diseases. In the U.S., most people with coverage from Medicaid and the Children's Health Insurance Program (CHIP) will have guaranteed coverage of all vaccines recommended by the Advisory Committee on Immunization Practice.
Foreign Smoking Cessation Vaccines: Do They Exist?
You may want to see also
Explore related products
$41.98 $124.99
RSV vaccine for pregnant women
The CDC recommends a respiratory syncytial virus (RSV) vaccine for pregnant women to protect their babies from severe RSV disease. The vaccine, Pfizer's Abrysvo, is recommended for administration during weeks 32 through 36 of pregnancy, ideally between September and January. This timing ensures protection for the baby during their first RSV season. The vaccine is administered as a single dose injection into the muscle.
The CDC advises that pregnant women discuss both maternal RSV vaccination and infant immunization with their healthcare providers to determine the best option for their family. If a pregnant woman has already received a maternal RSV vaccine during a previous pregnancy, the CDC does not recommend another dose during subsequent pregnancies. However, if the mother was not vaccinated during the current pregnancy, the infant should receive nirsevimab during October-March to protect against RSV.
Abrysvo has been shown to be effective in reducing the risk of severe lower respiratory tract disease (LRTD) caused by RSV in infants. Clinical studies have demonstrated that Abrysvo reduced the risk of severe LRTD by 81.8% within 90 days after birth and 69.4% within 180 days after birth, compared to a placebo. The vaccine is generally well-tolerated, but some side effects, such as pain, redness, and swelling at the injection site, fatigue, fever, and headache, may occur.
It is important to note that the CDC's recommendations for RSV vaccination focus primarily on individuals at the highest risk for severe illness from RSV. This includes adults over the age of 75 and those between 60 and 74 with certain chronic health conditions or living in nursing homes. The CDC also emphasizes that the RSV vaccine is not currently an annual vaccine, and protection from the vaccine lasts more than a year.
Vaccine Route and Site: What's the Right Combo?
You may want to see also
Frequently asked questions
The CDC recommends the RSV vaccine for all adults 75 years old or older.
The CDC recommends that adults between 60-74 years old who are at an increased risk of severe RSV also receive the vaccine.
Side effects may include pain, redness, or swelling in the location where you received the shot, tiredness, aches in your body or joints, fever, nausea, or diarrhea.
RSV, or respiratory syncytial virus, is a highly contagious virus that causes infections of the lungs and breathing passages.
There are three RSV vaccines for adults 60 years old or older: ABRYSVO® from Pfizer, AREXVY® from GSK, and mRESVIA®, manufactured by Moderna.
